Japan's Shionogi Says COVID Pill Reaches Endpoint In Phase I...| MENAFN.COM

Wednesday, 07 December 2022 07:41 GMT

Japan's Shionogi Says COVID Pill Reaches Endpoint In Phase III Trial


(MENAFN- Trend News Agency)

Japan's Shionogi & Co Ltd said on Wednesday its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared to a placebo in a Phase III trial in Asia, reports citing .

The drug, a protease inhibitor known as ensitrelvir, met its primary endpoint in a trial conducted among predominantly vaccinated patients with mild to moderate cases of COVID-19, the company said in a statement.

Regulatory authorities in Japan previously denied emergency approval for use of the pill, saying they wanted to see more data on its effectiveness. read more

Shionogi has global aspirations for the drug, also known as S-217622 and by the brand name Xocova, which would compete with COVID-19 pills from U.S. Pfizer Inc and Merck & Co Inc (MRK.N) that have already been approved in Japan and elsewhere.

The company has signed an agreement to sell about a million doses to the government, pending the drug's approval.

MENAFN28092022000187011040ID1104935824


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.